ICON experts frequently author or contribute to industry trade press. The following are some recent articles.
Transforming clinical trials in a rapidly shifting landscape
Dr Ute Berger outlines how ICON is transforming clinical trials in a rapidly shifting landscape in the Executive Interview in Drug Development & Delivery.
Data doesn't cut it - Payer engagement requires a humanistic approach
Earlene Biggs shares the key elements of an effective strategy to engage with healthcare decision-makers.
Developing mRNA vaccine technology
In this article, Dinah Knotts speaks about mRNA vaccine technology and what further opportunities it can offer in fighting infectious diseases.
Decentralised clinical trials and sites: friend or foe?
Emily Mitchell contributes to this piece in Clinical Trials Arena on the role of sites in a DCT setting.
Due diligence and beyond
Dr. Sandra Eagle outlines how due diligence has evolved from a discrete standalone technical assessment of an asset, to now being an integrated part of the holistic development continuum of an asset.
LEO Pharma enters clinical trial partnership with ICON
This news article, published on PM Live, highlights how the partnership will advance trial execution within medical dermatology.
LEO Pharma and ICON plc collaborate to improve outcomes for dermatology patients
This article, published on Outsourcing Pharma, covers the strategic partnership between LEO Pharma and ICON.
The contribution of companies during the Covid-19 pandemic
Rose Kidd outlines the role ICON played in the search for vaccines and treatments for Covid-19 in the American Chamber of Commerce Ireland 2023 US-Ireland Business Report.
LEO Pharma and ICON partner for clinical trial execution in dermatology
This news article outlines how the collaboration is expected to provide access to innovative clinical trials as well as help to launch new medicines.
LEO Pharma and ICON enter strategic partnership
ICON and LEO Pharma have announced a strategic partnership to scale patient-centric and cost-effective clinical trials.